Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1992 1
1997 1
1998 2
1999 3
2000 2
2005 1
2008 1
2009 1
2020 1
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

15 results
Results by year
Filters applied: . Clear all
Page 1
TAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, β-Catenin, and TRK pathways.
Miura A, Sootome H, Fujita N, Suzuki T, Fukushima H, Mizuarai S, Masuko N, Ito K, Hashimoto A, Uto Y, Sugimoto T, Takahashi H, Mitsuya M, Hirai H. Miura A, et al. Among authors: masuko n. Invest New Drugs. 2021 Jun;39(3):724-735. doi: 10.1007/s10637-020-01019-9. Epub 2021 Jan 6. Invest New Drugs. 2021. PMID: 33409897
NE-dlg, a mammalian homolog of Drosophila dlg tumor suppressor, induces growth suppression and impairment of cell adhesion: possible involvement of down-regulation of beta-catenin by NE-dlg expression.
Hanada N, Makino K, Koga H, Morisaki T, Kuwahara H, Masuko N, Tabira Y, Hiraoka T, Kitamura N, Kikuchi A, Saya H. Hanada N, et al. Among authors: masuko n. Int J Cancer. 2000 May 15;86(4):480-8. doi: 10.1002/(sici)1097-0215(20000515)86:4<480::aid-ijc6>3.0.co;2-6. Int J Cancer. 2000. PMID: 10797259 Free article.
15 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page